超低分割全乳放疗临床实施的前瞻性电子患者报告结局监测
单中心前瞻性队列纳入308例非转移性乳腺癌保乳术后无淋巴结及瘤床加量照射患者,分别接受HF(15×2.67 Gy)或UHF(5×5.2 Gy)IMRT/VMAT,通过自动化ePROM平台在多个时间点评估不良反应。除HF末次分割皮肤反应和24个月疼痛严重程度较高外,两组不良事件严重程度无临床意义差异,UHF可安全整合入临床常规。
要点
- UHF全乳放疗采用IMRT/VMAT未增加患者报告的急性或晚期不良事件。
- HF末次分割放射性皮肤反应和24个月疼痛严重程度高于UHF。
- ePROM平台自动化监测依从性高,24个月脱落率约30%。
核心结论
- UHF全乳放疗采用现代IMRT/VMAT技术,与HF相比未增加患者报告的急性或晚期不良事件,确认可安全整合入临床常规。
研究设计与样本
- 单中心前瞻性队列研究,连续纳入308例非转移性乳腺癌保乳术后、无淋巴结及无瘤床加量照射患者,接受HF(15×2.67 Gy)或UHF(5×5.2 Gy)。
- 通过自动化ePROM平台在首次和末次分割及3、6、9、12、24个月评估PRO-CTCAE条目(瘙痒、放射性皮肤反应、皮肤变暗、疼痛和乳房压痛)。
- 采用人群平均有序广义估计方程纵向建模不良事件分级,校正年龄、手术和激素治疗。
主要发现
- 队列共308例,其中UHF组177例、HF组131例,ePROM完成依从性高,24个月脱落率30%。
- 两组不良事件严重程度无临床意义差异,但HF末次分割放射性皮肤反应较高(OR=2.70)。
- 24个月时仅疼痛严重程度存在差异,HF组比值比更高(OR=3.08),其他终点组间无显著差异。
关键数值与推荐
- HF方案为15次×2.67 Gy,UHF方案为5次×5.2 Gy。
- HF末次分割放射性皮肤反应OR=2.70,24个月疼痛OR=3.08。
临床怎么用
- UHF全乳放疗联用IMRT/VMAT可安全用于保乳术后无淋巴结及无瘤床加量照射患者,不增加患者报告的不良事件。
- 可利用自动化ePROM平台在治疗期间及随访中纵向监测不良反应。
局限性
- 单中心前瞻性队列设计,非随机对照。
- 24个月ePROM脱落率为30%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Clinical trials on ultrahypofractionated (UHF) whole‑breast radiotherapy demonstrated non‑inferiority to moderate hypofractionation (HF). However, real-world evidence using modern treatment techniques, captured by fully automated electronic patient-reported outcome measures (ePROM), remains limited. This study prospectively evaluated the clinical implementation of UHF whole-breast radiotherapy using intensity-modulated/volumetric arc radiotherapy (IMRT/VMAT) with ePROM-based adverse event monitoring. MATERIALS AND METHODS: In this single-centre prospective cohort, consecutive non-metastatic breast cancer patients (breast conserving surgery, no nodal and no boost irradiation) received either HF (15 × 2.67 Gy) or UHF (5 × 5.2 Gy). Acute and late side effects were assessed using PRO‑CTCAE items (itching, radiation skin reaction, skin darkening, pain and breast tenderness) via an automated ePROM platform at the first and last fraction, and at 3, 6, 9, 12, and 24 months. Longitudinal adverse event grades were modelled using population-averaged ordinal generalised estimating equations adjusted for age, surgery, and hormone therapy. RESULTS: The patient cohort of 308 patients included 177 UHF and 131 HF patients. ePROM completion adherence was high (30% drop-out at 24 months). No clinically meaningful differences in adverse event severity were observed between both regimens, except for higher radiation skin reactions at the last fraction in HF (odd ratio (OR) = 2.70). At 24 months, only pain severity differed, with higher odds for HF (OR = 3.08). Other endpoints showed no significant between-group differences. CONCLUSION: UHF whole-breast radiotherapy delivered with contemporary IMRT/VMAT showed no increase in acute or late patient-reported adverse events compared with HF, confirming its safe integration into clinical routine.
引用
- Knäusl B, Heilemann G, Andexlinger L, et al. Prospective monitoring of the clinical implementation of ultrahypofractionated whole-breast radiotherapy using electronic patient-reported outcome measures. Clin Transl Radiat Oncol. 2026. PMID: 41908647. doi:10.1016/j.ctro.2026.101148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。